Compare Heron Therapeutics Inc (HRTX) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs IQIYI Inc - ADR — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while IQIYI Inc - ADR trades at $1 (market cap $979.50M). The key difference: IQIYI Inc - ADR is far larger — about 13.2× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (3,668,095 versus 1,962,950). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and IQIYI Inc - ADR for 55 Days on average.
| HRTX | IQ | |
|---|---|---|
Market Cap | $74.04M | $979.50M |
Volume | 3,668,095 | 1,962,950 |
Sector | Health | Media |
52-Week High | $1.49 | $2.35 |
52-Week Low | $0.27 | $0.86 |
Typical Hold Time | 35 Days | 55 Days |
Enterprise Value | $180.78M | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
iQIYI (IQ) trades at $1.01, showing no change in the latest session. The stock presents a mixed picture with strong analyst support (50% buy ratings) but concerning fundamentals including negative net income margins and declining revenue. Recent earnings have consistently beaten expectations despite losses, while the company is aggressively pursuing AI-driven content production to reset its cost structure amid streaming business contraction.
The outlook remains challenging with revenue declining to $27.3 billion in 2025 and projected to fall further to $26.0 billion in 2026. While valuation metrics appear attractive with P/S of 0.25 and P/B of 0.52, persistent losses and competitive pressures in Chinese streaming markets create significant headwinds. The AI content pivot offers potential but requires successful execution to justify current analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
